Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00710385 · ClinicalTrials.gov registry record · Phase 3

Abuse Liability of Suboxone Versus Subutex

A Phase 3 study, sponsored by New York State Psychiatric Institute.

Completed
Registry status
Phase 3
Development phase
19
Enrollment target

NCT00710385 is a Phase 3 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 19 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00710385, a Phase 3 study, has completed, sponsored by New York State Psychiatric Institute.

COMPLETED
Registry status
Phase 3
Development phase
19 participants
Enrollment target

Study Summary

The study is designed to compare the abuse liabilities of intravenous buprenorphine and buprenorphine/naloxone in individuals who are physically dependent on sublingual buprenorphine. We hypothesize that the abuse liability of buprenorphine/naloxone is lower than that of buprenorphine alone.

Interventions

  • DRUG Naloxone
  • DRUG Heroin
  • DRUG Low Bup Dose
  • DRUG High Bup Dose
  • DRUG Low Bup/Nal Dose

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2007-09
Est. Completion 2008-08
Phase Phase 3

What the Registry Record Tells You About NCT00710385

The ClinicalTrials.gov registry entry for NCT00710385 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 5 interventions - of which Naloxone is the first listed.

NCT00710385 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00710385 about?

NCT00710385 is a clinical study titled "Abuse Liability of Suboxone Versus Subutex". The study is designed to compare the abuse liabilities of intravenous buprenorphine and buprenorphine/naloxone in individuals who are physically dependent on sublingual buprenorphine. We hypothesize that the abuse liability of buprenorphine/naloxone is lower than that of buprenorphine alone.

What is the current status of trial NCT00710385?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 19 participants. The study started on 2007-09. Estimated completion is 2008-08.

What interventions are being tested in trial NCT00710385?

The interventions under investigation include: Naloxone (DRUG), Heroin (DRUG), Low Bup Dose (DRUG), High Bup Dose (DRUG), Low Bup/Nal Dose (DRUG).

Who is sponsoring clinical trial NCT00710385?

This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.